Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Amyloid Fibrils03:03

Amyloid Fibrils

10.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust bionic distributed multimodal flexible sensor for extreme-condition sensing and intelligent operation.

Communications engineering·2026
Same author

Endoscopic transnasal sphenopalatine ganglion block for chronic craniofacial pain.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

Plasmonic magnetic nanoparticles-enabled universal enrichment, photothermal lysis, and duplex CRISPR detection of bacteria in urine samples.

Biosensors & bioelectronics·2026
Same author

Detection and clinical analysis of human coronavirus infection in pediatric patients with acute respiratory tract infection in the Xiamen Area, China, 2022-2024.

BMC infectious diseases·2026
Same author

Debunking myths in facial pain diagnosis for the pain practitioner.

Regional anesthesia and pain medicine·2026
Same author

Risk of seizure in patients with prostate cancer treated with enzalutamide in China: a noninterventional study.

Therapeutic advances in drug safety·2025

Related Experiment Video

Updated: May 2, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

22.4K

Betaine suppressed Aβ generation by altering amyloid precursor protein processing.

Xiu-Ping Liu1, Xiang Qian, Yue Xie

  • 1Department of Clinical Laboratory, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, 310007, China, 470299188@qq.com.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|February 20, 2014
PubMed
Summary

Betaine, a choline metabolite, may protect against Alzheimer's disease (AD) by reducing amyloid-beta (Aβ) production. This study shows Betaine alters amyloid precursor protein (APP) processing, decreasing Aβ levels.

More Related Videos

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.1K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

10.7K

Related Experiment Videos

Last Updated: May 2, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

22.4K
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.1K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

10.7K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Betaine is an endogenous choline metabolite found in plants and seafood.
  • Clinically, betaine is used for hyperlipidemia, coronary atherosclerosis, and fatty liver.
  • Emerging evidence links betaine to mitigating homocysteine-induced neuronal damage and Alzheimer's disease (AD) pathology.

Purpose of the Study:

  • To investigate betaine's effect on amyloid-beta (Aβ) production.
  • To explore the mechanism by which betaine influences amyloid precursor protein (APP) processing.

Main Methods:

  • Utilized N2a cells engineered to express a Swedish mutant of APP.
  • Assessed the impact of betaine on APP secretase activities (α-secretase and β-secretase).

Main Results:

  • Betaine treatment led to a reduction in Aβ levels in the studied cell model.
  • Betaine was found to enhance α-secretase activity.
  • Betaine was observed to decrease β-secretase activity.

Conclusions:

  • Betaine may offer neuroprotection by modulating APP processing pathways.
  • The findings suggest betaine's potential therapeutic role in reducing Aβ production, a key factor in AD pathogenesis.